CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 35 target
Drug / intervention
Serplulimab+SOXdrug
Likely dose
Not stated in record
Key inclusion· 7
  • ✓Histologically documented adenocarcinoma of gastric or gastroesophageal junction
  • ✓Stage T3-4aN+M0 disease
  • ✓Age 18-75 years
  • ✓Surgeon considers lesion resectable
Key exclusion· 29
  • ✕Distant metastasis or unresectable primary lesion
  • ✕T1 or T2 lesions
  • ✕History of chemotherapy, radiation, immunotherapy, or radical resection for gastric cancer
  • ✕Active or refractory autoimmune disease

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06496789
NCT06496789Phase 2RecruitingUpdate OverdueUpdated 23mo ago · Completion was 18mo ago
Enrollment Stalled
Long Recruiting
Update Overdue
CompareCT.gov

Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer: a Single-arm Phase 2 Trial

Tianjin Medical University Cancer Institute and Hospital·interventional·Posted Jul 11, 2024·Updated Jul 11, 2024

In Brief

A Phase 2 clinical trial evaluating Serplulimab+SOX for Gastric Adenocarcinoma. Currently recruiting, targeting 35 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

evaluate efficacy and safety of neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Adenocarcinoma
CountriesChina
Collaborators--

Timeline

Phase 2RecruitingOverdue
202420252026
First PostedJul 11, 2024
Enrollment StartMay 27, 2023
Primary CompletionDec 30, 2024
Study CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 2.0 years ago

Interventions

Serplulimab+SOXdrug

Serplulimab+Oxaliplatin+S1